Figure 4.
Labeled thrombin-activatable fibrinolysis inhibitor (TAFI) localized to both C-terminal lysine exposed fibrin fibers and the surfaces of activated platelets. (A) Representative sequential (a-e at the indicated times) high magnification images (63× objective) of Alexa Fluor 488-labeled fibrinogen (fbg-488, top, green), Alexa Fluor 568-labeled plasminogen (plg-568, second from top, red), and Alexa Fluor 647-labeled TAFI (TAFI-647; third from top, blue). (B) Images of fbg-488, plg-568, TAFI-647, and overlay at 20 minutes, 40 seconds from the start of video capture, in the presence of 1 mM ε-aminocaproic acid, a lysine analog.

Labeled thrombin-activatable fibrinolysis inhibitor (TAFI) localized to both C-terminal lysine exposed fibrin fibers and the surfaces of activated platelets. (A) Representative sequential (a-e at the indicated times) high magnification images (63× objective) of Alexa Fluor 488-labeled fibrinogen (fbg-488, top, green), Alexa Fluor 568-labeled plasminogen (plg-568, second from top, red), and Alexa Fluor 647-labeled TAFI (TAFI-647; third from top, blue). (B) Images of fbg-488, plg-568, TAFI-647, and overlay at 20 minutes, 40 seconds from the start of video capture, in the presence of 1 mM ε-aminocaproic acid, a lysine analog.

Close Modal

or Create an Account

Close Modal
Close Modal